График акции Greenwich LifeSciences, Inc.
Расширенный график
Простой график
О компании Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.| IPO date | 2020-09-25 |
|---|---|
| ISIN | US3968791083 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://greenwichlifesciences.com |
| Цена ао | 20.32 |
| Изменение цены за день: | -3.12% (11.87) |
|---|---|
| Изменение цены за неделю: | -7.18% (12.39) |
| Изменение цены за месяц: | -21.07% (14.57) |
| Изменение цены за 3 месяца: | -18.73% (14.15) |
| Изменение цены за полгода: | -34.58% (17.58) |
| Изменение цены за год: | +9.32% (10.52) |
| Изменение цены за 3 года: | -59.62% (28.48) |
| Изменение цены за 5 лет: | 0% (11.5) |
| Изменение цены за 10 лет: | 0% (11.5) |
| Изменение цены с начала года: | -11.33% (12.97) |
|
|
Недооценка
|
Эффективность
|
|||||||||||||||||||||||||||||||||||||
Дивиденды
|
Долг
|
Импульс роста
|
|||||||||||||||||||||||||||||||||||||
| Институционалы | Объем | Доля, % |
|---|---|---|
| Vanguard Group Inc | 221682 | 1.73 |
| Blackrock Inc. | 57148 | 0.44 |
| Ameriprise Financial, Inc. | 53647 | 0.42 |
| Geode Capital Management, LLC | 46816 | 0.36 |
| Renaissance Technologies, LLC | 36600 | 0.28 |
| Northern Trust Corporation | 20983 | 0.16 |
| 683 Capital Management LLC | 19604 | 0.15 |
| Qube Research & Technologies Ltd | 14714 | 0.11 |
| JANE STREET GROUP, LLC | 14005 | 0.11 |
| State Street Corporation | 13002 | 0.1 |
| ETF | Доля, % | Доходность за год, % | Дивиденды, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.02306 | 17.09 | 1.54048 |
| Vanguard Russell 2000 Growth ETF | 0.01 | 23.05 | 0.60264 |
iShares Russell 2000 Growth ETF
|
0.00627 | 38.04 | 0.6026 |
ProShares UltraPro Russell2000
|
0.00192 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.0005 | 5.92 | 1.47892 |
| Vanguard Russell 2000 ETF | 0 | 17.16 | 1.48801 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| Руководитель | Должность | Оплата | Год рождения |
|---|---|---|---|
| Mr. Snehal S. Patel | CEO, CFO & Director | 1.09M | 1964 (61 год) |
| Mr. Eric Rothe | Founder & Independent Director | 65.64k | 1976 (49 лет) |
| Dr. Frank Joseph Daugherty M.D. | Chief Medical Officer & Director | N/A | 1951 (74 года) |
| Dr. Jaye L. Thompson Ph.D. | Vice President Clinical & Regulatory Affairs | N/A | 1966 (59 лет) |
| Dr. Christine T. Fischette Ph.D. | VP of Business Development | N/A | 1951 (74 года) |
Адрес: United States, Stafford. TX, Building 14 - открыть в Google картах, открыть Яндекс картах
Сайт: https://greenwichlifesciences.com
Сайт: https://greenwichlifesciences.com
